+Compare
AXLA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
16.86M

AXLA Price Prediction, Axcella Health AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for AXLA with price predictions
07:00 PM EST Nov 26, 2023

Momentum Indicator for AXLA turns negative, indicating new downward trend

AXLA saw its Momentum Indicator move below the 0 level on November 21, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In of the 82 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for AXLA turned negative on November 27, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 50-day moving average for AXLA moved below the 200-day moving average on November 20, 2023. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXLA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for AXLA entered a downward trend on November 21, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AXLA advanced for three days, in of 206 cases, the price rose further within the following month. The odds of a continued upward trend are .

AXLA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AXLA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.084) is normal, around the industry mean (20.463). P/E Ratio (0.000) is within average values for comparable stocks, (137.276). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.954). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (329.780).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXLA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I. Advisor
published Earnings

AXLA is expected to report earnings to fall 96.00% to -5 cents per share on November 15

Axcella Health AXLA Stock Earnings Reports
Q3'23
Est.
$-0.05
Q2'23
Missed
by $1.20
Q1'23
Beat
by $0.07
Q4'22
Missed
by $0.02
Q3'22
Beat
by $0.03
The last earnings report on August 03 showed earnings per share of -125 cents, missing the estimate of -5 cents. With 121.88K shares outstanding, the current market capitalization sits at 16.86M.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 467.58B. NVO holds the highest valuation in this group at 467.58B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 7%. SEPSF experienced the highest price growth at 145%, while TMBR experienced the biggest fall at -77%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was 1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of first-in-class precision therapeutic solutions to diseases with a focus on restoring amino acid biology

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
P.O. Box 1270
Phone
+1 857 320-2200
Employees
11
Web
https://www.axcellahealth.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALTO2.440.04
+1.67%
Alto Ingredients
SCSC32.02-0.06
-0.19%
ScanSource
NWG5.19-0.04
-0.76%
NatWest Group plc
OP2.21-0.02
-0.90%
OceanPal
PDCO31.89-0.66
-2.03%
Patterson Companies

AXLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AXLA has been loosely correlated with ADTX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AXLA jumps, then ADTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AXLA
1D Price
Change %
AXLA100%
-37.50%
ADTX - AXLA
46%
Loosely correlated
-2.20%
KA - AXLA
37%
Loosely correlated
-1.59%
MDGL - AXLA
34%
Loosely correlated
+0.89%
CELC - AXLA
28%
Poorly correlated
+1.75%
SNPX - AXLA
28%
Poorly correlated
-9.72%
More